The estimated Net Worth of Philip J. Vickers is at least 352 千$ dollars as of 7 July 2021. Philip Vickers owns over 4,800 units of AvroBio Inc stock worth over 6,720$ and over the last 10 years he sold AVRO stock worth over 0$. In addition, he makes 344,865$ as Independent Director at AvroBio Inc.
Philip has made over 2 trades of the AvroBio Inc stock since 2018, according to the Form 4 filled with the SEC. Most recently he bought 4,800 units of AVRO stock worth 40,080$ on 7 July 2021.
The largest trade he's ever made was buying 4,800 units of AvroBio Inc stock on 7 July 2021 worth over 40,080$. On average, Philip trades about 442 units every 67 days since 2015. As of 7 July 2021 he still owns at least 4,800 units of AvroBio Inc stock.
You can see the complete history of Philip Vickers stock trades at the bottom of the page.
Dr. Philip J. Vickers, Ph.D., serves as Director of the Company. Dr. Vickers is the president and chief executive officer and a member of the board of directors of Northern Biologics Inc., a biotechnology company, and has served in such roles since November 2017. From June 2013 until June 2017, Dr. Vickers served as global head of research and development and a member of the executive committee of Shire plc, a biotechnology company focused on the development of therapies for the treatment of rare and specialty conditions. From October 2010 to September 2013, Dr. Vickers served as the senior vice president, head of research and development, human genetic therapies at Shire. Prior to Shire, Dr. Vickers held positions of increasing responsibility in research and development at Merck & Co., Inc., Pfizer Inc., Boehringer-Ingelheim International GmbH and Resolvyx Pharmaceuticals, Inc. Dr. Vickers serves on the board of directors of Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology company, and as a scientific advisor to the PTEN Research Foundation. Dr. Vickers obtained his Ph.D. in biochemistry from the University of Toronto, which was followed by postdoctoral research in mechanisms of multidrug resistance in breast cancer at the National Cancer Institute in Bethesda, Maryland.
As the Independent Director of AvroBio Inc, the total compensation of Philip Vickers at AvroBio Inc is 344,865$. There are 8 executives at AvroBio Inc getting paid more, with Birgitte Volck having the highest compensation of 4,384,270$.
Philip Vickers is 60, he's been the Independent Director of AvroBio Inc since 2019. There are 4 older and 15 younger executives at AvroBio Inc. The oldest executive at AvroBio Inc is Christopher Paige, 67, who is the Independent Director.
Philip's mailing address filed with the SEC is C/O AVROBIO, INC., 100 TECHNOLOGY SQUARE, 6TH FLOOR, CAMBRIDGE, MA, 02139.
Over the last 6 years, insiders at AvroBio Inc have traded over 3,066,308$ worth of AvroBio Inc stock and bought 2,395,057 units worth 31,037,133$ . The most active insiders traders include Braden Michael Leonard、Bruce Booth、Venture Fund X, L.P.Atlas V.... On average, AvroBio Inc executives and independent directors trade stock every 102 days with the average trade being worth of 206,675$. The most recent stock trade was executed by Braden Michael Leonard on 13 May 2024, trading 766,635 units of AVRO stock currently worth 973,626$.
clinical stage company focused on delivering step-change cell & gene therapies targeting cancer and rare disease.
AvroBio Inc executives and other stock owners filed with the SEC include: